PLA2G7 and systemic lupus erythematosus: While modest increases have been earlier observed in patients with rheumatoid arthritis compared to controls with non-inflammatory arthritides (42), systemic sclerosis (43), or lupus anticoagulant-positive or aβ2GPI IgG positive sera (44), other studies in rheumatoid arthritis (45), systemic lupus erythematosus (23), juvenile rheumatoid arthritis (46), and Crohn’s disease (24), showed opposite results with a reduced Lp-PLA2 plasma activity being detected.